Evidence map›Paper›PMID 35353237›Full record

ArticleBreast cancer research and treatment2022

Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.

Gabriela E S Felix, Rodrigo Santa Cruz Guindalini, Yonglan Zheng, Tom Walsh, Elisabeth Sveen, Taisa Manuela Machado Lopes, Juliana Côrtes, Jing Zhang, Polyanna Carôzo, Irlânia Santos and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Genes · 2024
    Article
  6. Meta-Analysis of Breast Cancer Risk for Individuals with PALB2 Pathogenic Variants.medRxiv : the preprint server for health sciences · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Gabriela E S FelixInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Rodrigo Santa Cruz GuindaliniCentro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de São Paulo (ICESP), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Yonglan ZhengDepartment of Medicine, Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, Illinois, USA.
Tom WalshDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.
Elisabeth SveenDepartment of Medicine, Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, Illinois, USA.
Taisa Manuela Machado LopesInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Juliana CôrtesInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Jing ZhangDepartment of Medicine, Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, Illinois, USA.
Polyanna CarôzoInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Irlânia SantosInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Thaís Ferreira BonfimInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Bernardo GaricocheaGrupo Oncoclínicas, São Paulo, São Paulo, Brazil.
Maria Betânia Pereira TorallesInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Roberto MeyerInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Eduardo Martins NettoLaboratório de Pesquisa em Infectologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Kiyoko Abe-SandesInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Mary-Claire KingDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.
Ivana Lucia de Oliveira NascimentoInstituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Olufunmilayo I OlopadeDepartment of Medicine, Center for Clinical Cancer Genetics and Global Health, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, Illinois, 60637-1470, USA. folopade@medicine.bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-9936-1599
Universidade Federal da Bahia · BRUniversity of Chicago · USUniversity of Washington Medical Center · USFleury S.A. (Brazil) · BRInstituto do Câncer do Estado de São Paulo · BR

Funding

Developing an Oncology Workforce for the 21st Century - Renewal 01K12CA139160 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F., SMITH, SONALI · 2010 to 2024
$10.6M
UChicago Interdisciplinary Cancer Health Disparities SPOREP20CA233307 · NCI · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, NANDA, RITA · 2018 to 2020
$3.4M
NCI NIH HHS K12 CA139160NCI NIH HHS P20 CA233307
6 · The paper itself

Abstract

purposeThere is a paucity of data on the spectrum and prevalence of pathogenic variants among women of African ancestry in the Northeast region of Brazil.

methodsWe performed BROCA panel sequencing to identify inherited loss-of-function variants in breast cancer susceptibility genes among 292 Brazilian women referred to a single institution cancer risk assessment program.

resultsThe study included a convenient cohort of 173 women with invasive breast cancer (cases) and 119 women who were cancer-free at the time of ascertainment. The majority of the women self-reported as African-descended (67% for cases and 90.8% for unaffected volunteers). Thirty-seven pathogenic variants were found in 36 (20.8%) patients. While the spectrum of pathogenic variants was heterogeneous, the majority (70.3%) of the pathogenic variants were detected in high-risk genes BRCA1, BRCA2, PALB2, and TP53. Pathogenic variants were also found in the ATM, BARD1, BRIP1, FAM175A, FANCM, NBN, and SLX4 genes in 6.4% of the affected women. Four recurrent pathogenic variants were detected in 11 patients of African ancestry. Only one unaffected woman had a pathogenic variant in the RAD51C gene. Different risk assessment models examined performed well in predicting risk of carrying germline loss-of-function variants in BRCA1 and/or BRCA2 in breast cancer cases.

conclusionThe high prevalence and heterogenous spectrum of pathogenic variants identified among self-reported African descendants in Northeast Brazil is consistent with studies in other African ancestry populations with a high burden of aggressive young onset breast cancer. It underscores the need to integrate comprehensive cancer risk assessment and genomic testing in the management of newly diagnosed Black women with breast cancer across the African Diaspora, enabling improved cancer control in admixed underserved and understudied populations.

Indexed as

Breast NeoplasmsBrazilBRCA1 ProteinBRCA2 ProteinDNA HelicasesFemaleGenes, BRCA2Genetic Predisposition to DiseaseGerm-Line MutationHumansMutationBRCA1 ProteinBRCA2 ProteinDNA HelicasesFANCM protein, humanBraziliansBreast cancerBROCA panelGenetic testing

Identifiers

PMID35353237
PMCPMC9090684
OpenAlexW4220760054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.